GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karyopharm Therapeutics Inc (FRA:25K) » Definitions » Interest Expense

Karyopharm Therapeutics (FRA:25K) Interest Expense : €-25.1 Mil (TTM As of Jun. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Karyopharm Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Karyopharm Therapeutics's interest expense for the three months ended in Jun. 2024 was € -8.3 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2024 was €-25.1 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Karyopharm Therapeutics's Operating Income for the three months ended in Jun. 2024 was € -26.1 Mil. Karyopharm Therapeutics's Interest Expense for the three months ended in Jun. 2024 was € -8.3 Mil. Karyopharm Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Karyopharm Therapeutics Interest Expense Historical Data

The historical data trend for Karyopharm Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karyopharm Therapeutics Interest Expense Chart

Karyopharm Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.08 -22.31 -23.05 -23.60 -21.85

Karyopharm Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.34 -5.69 -5.69 -5.41 -8.31

Karyopharm Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-25.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Karyopharm Therapeutics  (FRA:25K) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Karyopharm Therapeutics's Interest Expense for the three months ended in Jun. 2024 was €-8.3 Mil. Its Operating Income for the three months ended in Jun. 2024 was €-26.1 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2024 was €178.4 Mil.

Karyopharm Therapeutics's Interest Coverage for the quarter that ended in Jun. 2024 is calculated as

Karyopharm Therapeutics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Karyopharm Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karyopharm Therapeutics Inc (FRA:25K) » Definitions » Interest Expense
Comparable Companies
ABEO BDTX SGMO GMDA OCGN MNOV NYMXF PRQR ALDX RLMD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
KPTI:USA
Address
85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459
Website
https://www.karyopharm.com
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Karyopharm Therapeutics Headlines

No Headlines